Sembragiline

Drug Profile

Sembragiline

Alternative Names: EVT-302; RG-1577; RO-4602522

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Roche
  • Developer Evotec AG; Roche
  • Class Acetanilides; Nootropics; Pyrrolidines; Small molecules; Smoking cessation therapies
  • Mechanism of Action Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Discontinued Smoking withdrawal

Most Recent Events

  • 08 Sep 2016 Phase II development is ongoing in Australia, Canada, Czech Republic, France, Germany, Italy, Poland, South Korea, Spain, Sweden, United Kingdom and USA (Evotec pipeline, September 2016)
  • 30 Jun 2015 Interim efficacy and safety data from a phase-II trial in Alzheimer's disease released by Roche (NCT01677754)
  • 22 Jun 2015 No recent reports on development identified - Phase-I for Alzheimer's disease (In volunteers) in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top